Pharmaceuticals News and Research

RSS

Chicago hospitals see little change in ER visits; Calif. probes Anthem's provider lists

The Chicago Sun-Times examines the health law's effect on local emergency rooms, while the Los Angeles Times reports that state officials are investigating whether Anthem Blue Cross and Blue Shield of California violated state law by posting inaccurate provider lists.

24 Jun 2014

Study on digestion of milk could lead to development of new formulas for premature babies

A new study on the digestion of milk could lead to the development of new formulas for premature babies, weight loss drinks and potentially new drug delivery systems.

23 Jun 2014

Private insurers clamp down on drug prices

More health plans are refusing to cover certain brand-name drugs unless drugmakers offer discounts for them, reports The New York Times.

23 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

First Edition: June 23, 2014

Today's early morning highlights from the major news organizations, including news stories about healthcare.gov management changes.

23 Jun 2014

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Alexion Pharmaceuticals, Inc. and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.

23 Jun 2014

Definiens closes €15M financing round to expand into digital tissue diagnostics

Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million.

23 Jun 2014

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.

23 Jun 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

This report estimated the effect of the Affordable Care Act (ACA) on 14 large and diverse cities: Los Angeles, Chicago, Houston, Philadelphia, Phoenix, Indianapolis, Columbus, Charlotte, Detroit, Memphis, Seattle, Denver, Atlanta, and Miami.

21 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Merck commences cash tender offer to purchase Idenix Pharmaceuticals

Merck, known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. On June 09, 2014, Merck announced its intent to acquire Idenix.

20 Jun 2014

Researchers develop tissue engineered bone grafts for healing large bone defects

Bone is one of the most frequently transplanted tissues. And the demand is rising. Transplants treat large defects like those caused by trauma, complicated fractures, tumour resection or osteoporosis.

20 Jun 2014

ChromaDex enters into joint collaboration agreement with St. Jude Children's Research Hospital

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.

19 Jun 2014

Special issue discusses the value of academic technology transfer beyond money

The current special issue of Technology and Innovation is devoted to articles on both innovations in rural regions and general articles on technology and innovation, including an article from the National Academy of Inventors (NAI) by McDevitt et al.

19 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

Takeda decides to terminate development of orteronel for prostate cancer

Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer. The decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer (mCRPC).

19 Jun 2014

NCCN Reimbursement Resource App now available for patients and caregivers

The National Comprehensive Cancer Network announces the availability of the NCCN Reimbursement Resource App, a free resource through which patients with cancer, providers, case managers, and payers can search for available reimbursement resources and patient assistance programs for multiple cancer types and supportive care indications.

19 Jun 2014

Generic drug delays cost U.S. payers millions

Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal.

19 Jun 2014

IGI Laboratories submits third ANDA in 2014 to FDA

IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration, which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.

18 Jun 2014

Pharmaceuticals News and Research

Chicago hospitals see little change in ER visits; Calif. probes Anthem's provider lists

Study on digestion of milk could lead to development of new formulas for premature babies

Private insurers clamp down on drug prices

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

First Edition: June 23, 2014

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Definiens closes €15M financing round to expand into digital tissue diagnostics

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Celsion acquires all assets of EGEN

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Merck commences cash tender offer to purchase Idenix Pharmaceuticals

Researchers develop tissue engineered bone grafts for healing large bone defects

ChromaDex enters into joint collaboration agreement with St. Jude Children's Research Hospital

Special issue discusses the value of academic technology transfer beyond money

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Takeda decides to terminate development of orteronel for prostate cancer

NCCN Reimbursement Resource App now available for patients and caregivers

Generic drug delays cost U.S. payers millions

IGI Laboratories submits third ANDA in 2014 to FDA

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence